692TiP BRCA2men: An international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first-line of treatment in metastatic castration-resistant prostate cancer (mCRPC).

Saved in:
Bibliographic Details
Title: 692TiP BRCA2men: An international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first-line of treatment in metastatic castration-resistant prostate cancer (mCRPC).
Authors: Cattrini, C.1 (AUTHOR), Lozano Mejorada, R.1 (AUTHOR), Conteduca, V.2 (AUTHOR), Ruiz-Vico, M.3 (AUTHOR), Lolkema, M.P.4 (AUTHOR), Lorente, D.5 (AUTHOR), Sandhu, S.6 (AUTHOR), Romero Laorden, N.7 (AUTHOR), Loriot, Y.8 (AUTHOR), Azad, A.A.6 (AUTHOR), Costa, L.9 (AUTHOR), Vinceneux, A.10 (AUTHOR), Kanesvaran, R.11 (AUTHOR), Ürün, Y.12 (AUTHOR), Puente, J.13 (AUTHOR), Attard, G.3 (AUTHOR), Mehra, N.14 (AUTHOR), De Giorgi, U.2 (AUTHOR), Olmos Hidalgo, D.1 (AUTHOR), Castro Marcos, E.15 (AUTHOR)
Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS547-S548. 2p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2020.08.2086